Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles

David E. Kemp; Onur N. Karayal; Joseph R. Calabrese; Gary S. Sachs; Elizabeth Pappadopulos; Kathleen Ice; Cynthia Siu; Eduard Vieta

doi:10.1016/j.euroneuro.2011.06.005

Related publications

Article2010

Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder

Charles L. Bowden, Eduard Vieta, Kathleen Ice, Jeffrey H. Schwartz, Paul P. Wang, Mark Versavel

Article2009

A 6-month, Randomized, Placebo-controlled, Double Blind Trial of Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I Disorder

Eduard Vieta, Charles L. Bowden, Kathleen Ice, Oksana Gurtovaya, Jeffrey H. Schwartz, P. Wang

Article2001

Olanzapine as Long-Term Adjunctive Therapy in Treatment-Resistant Bipolar Disorder

Eduard Vieta, María Reinares, Bàrbara Corbella, Antoni Benabarre, Inmaculada Gilaberte, Francesc Colom, Anabel Martínez‐Arán, Cristòbal Gastó, M. Tohen

Article2009

P.3.a.030 A 6-month, double-blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder

Eduard Vieta, Charles L. Bowden, Kathleen Ice, Jeffrey H. Schwartz, P. Wang, M. Versavel, Onur N. Karayal

Article2022

T126. ADVANCING PHARMACOGENOMICS OF ANTICONVULSANT MOOD STABILIZER RESPONSE IN BIPOLAR DISORDER THROUGH THE MOOD STABILIZER GENOMICS (MOSTGEN) CONSORTIUM

Joanna M. Biernacka, Ada Man‐Choi Ho, Brandon J. Coombes, Susan L. McElroy, Alfredo Cuellar Barboza, Miguel A. Prieto, Eduard Vieta, Melvin G. McInnis, Bernhard T. Baune, Thomas G. Schulze, Boris Chaumette, Mirko Manchia, Alessandro Serretti, Martin Alda, Mark A. Frye